Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We saw a small decrease from the prior quarter due to typical summer seasonality and continue to see strong double-digit year-over-year growth in JELMYTO sales and what is our third full year of commercialization |
| The meaningful differentiated treatment profile of JELMYTO and its unique feature of being the only FDA-approved nonsurgical treatment indicated for low-grade UTUC continues to resonate with both patients and physicians |
| This growth in our top line reinforces our long-term belief in the low-grade UTUC opportunity |
| So we feel like we're in a very, very strong position with them and knowing exactly what they want to see, when they want to see it, and we're marching towards that |
| Both the ATLAS and ENVISION trials met their primary end points, demonstrating meaningful and compelling results overall and compared to the current standard of care, TURBT |
| A consistency and durability of response endpoints in ATLAS and OPTIMA, demonstrating a compelling therapeutic and safety profile throughout |
| So when you start to get down to 1, 2 years post-UGN-102, it's a very significant improvement on our bottom line, which will give us the resources that we need to continue to build this company over the long haul |
| We had the second strongest quarter in our history with continued momentum in our underlying business |
| Q3 was another strong quarter for JELMYTO |
| However, UGN-102 offers several distinct advantages over JELMYTO, including simpler administration and a much lighter operational lift |
| In addition, the growing body of data from real-world evidence studies continues to strengthen and reinforce JELMYTO's value proposition, supporting its multimodal use across various practice patterns and diverse presentations |
| We are pleased towards another strong quarter of year-over-year revenue growth |
| We believe there remains significant growth opportunity for JELMYTO as the first medicine ever approved for low-grade UTUC, bringing a differentiated chemoablative approach to patients |
| The closing of our $120 million private placement during the third quarter was an important milestone that significantly strengthened our balance sheet |
| Consistent growth and adoption for this product reinforces our optimism for the significant opportunity in low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 |
| Q3 2023 was a transformative quarter for UroGen following strong top line data from ATLAS and ENVISION and our pre-NDA Meeting with the FDA, we have a clear path forward towards an approval for UGN-102 in low-grade intermediate-risk nonmuscle-invasive bladder cancer |
| I'm very proud of the dedication and commitment across our organization as we remain focused on pioneering a new era in urologic and specialty cancer care |
| UroGen is at its strongest and most encouraging point in the company's history |
| We're pleased with the pace of growth for JELMYTO, especially when considering this is a rare disease treated in both community and academic centers |
| We will continue to drive growth and meaningful adoption through increasing sites of care and leveraging the growing body of real-world data, highlighting JELMYTO's meaningful value, and as part of a multimodal kidney-sparing approach to disease management |
| So that was 12, 13 advisers, very influential in the community that gave us really strong feedback |
| This potential milestone stands to become a major growth driver for UroGen, with a substantial market in the U.S |
| So what I'm hearing from colleagues is anticipation that's positive |
| They were very impressed with the data |
| But overall, the reimbursement, we expect -102 to be better than TURBT |
| Thus, we are encouraged that there are programs in development that may offer patients potentially better options than the current standard of care |
| Q3 2023 was also the second strongest revenue quarter for JELMYTO and low-grade upper tract urothelial carcinoma |
| So it was really more a matter of prospective, analysis plan and not being able to have that data in hand but again, very positive interaction |
| During the third quarter, further strengthening of the JELMYTO ramp and expansion of the JELMYTO user base was the result of several key factors, including continued commercial execution |
| It was the most positive they have ever been |
| Statement |
|---|
| I think it's been a tough market the last few weeks |
| Before we remark on the quarter, I must mention the October 7 attack in Israel and its impact on our Israeli colleagues, partners and investors |
| We can't do that |
| UroGen reported a net loss of $21.9 million or a basic and diluted net loss per ordinary share of $0.68 for the third quarter of 2023, as compared to $25.8 million or a basic and diluted net loss per ordinary shares of $1.13 for the same period in 2022 |
Please consider a small donation if you think this website provides you with relevant information